Internal Medicine, Endocrinology, Diabetes, & Metabolism · Red Bank, NJ
NPI
1043482631
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
225 Highway 35 North, Suite 102-B
Red Bank, NJ, 07701
Phone (732) 413-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$167K
4,944 services
Medicare patients, 2024
398
Average age 73
Drug cost, 2024
$4.2M
3,590 prescriptions
Company payments, 2025
$1,716
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Smita N Kargutkar was code J0897 (injection, denosumab, 1 mg), 3,060 times for 33 patients. In total Smita N Kargutkar billed 4,944 services in 16 codes, and Medicare paid $167K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,060 | 33 | $20.54 | $63K |
| 99214 Office E&M - Established | Office | 755 | 376 | $91.11 | $69K |
| 99457 E&M - Miscellaneous | Office | 224 | 28 | $37.51 | $8,403 |
| 95251 Test - Miscellaneous | Office | 162 | 80 | $25.17 | $4,077 |
| 99454 E&M - Miscellaneous | Office | 112 | 20 | $37.16 | $4,161 |
| 96401 Chemotherapy Administration | Office | 52 | 33 | $48.53 | $2,524 |
| 99458 E&M - Miscellaneous | Office | 47 | 22 | $29.95 | $1,408 |
| 99204 Office E&M - New | Office | 45 | 45 | $119.47 | $5,376 |
| 99215 Office E&M - Established | Office | 44 | 34 | $137.51 | $6,050 |
| 99213 Office E&M - Established | Office | 21 | 18 | $66.00 | $1,386 |
By year: 2022 $130K for 3,104 services; 2023 $175K for 4,001 services; 2024 $167K for 4,944 services.
Medicare prescription drug claims, 2024
In 2024, the drug Smita N Kargutkar prescribed most often to Medicare patients was Unithroid (Levothyroxine Sodium), with 304 prescriptions and refills. In total Smita N Kargutkar wrote 3,590 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Unithroid Levothyroxine Sodium | 304 | 854 | 94 | $9,662 |
| Ozempic Semaglutide | 303 | 595 | 70 | $549K |
| Metformin Hcl Er Metformin Hcl | 292 | 809 | 95 | $4,461 |
| Liothyronine Sodium Generic | 279 | 772 | 84 | $8,295 |
| Levothyroxine Sodium Generic | 202 | 517 | 57 | $2,021 |
| Synthroid Levothyroxine Sodium | 166 | 417 | 45 | $15K |
| Rosuvastatin Calcium Generic | 108 | 315 | 35 | $1,470 |
| Tresiba Flextouch U-200 Insulin Degludec | 98 | 248 | 29 | $136K |
| Farxiga Dapagliflozin Propanediol | 87 | 207 | 25 | $111K |
| Atorvastatin Calcium Generic | 71 | 177 | 19 | $739 |
| Jardiance Empagliflozin | 70 | 170 | 19 | $90K |
| Repaglinide Generic | 68 | 176 | 22 | $2,306 |
| Synjardy Xr Empagliflozin/Metformin Hcl | 67 | 137 | 14 | $70K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 63 | 176 | 31 | $9,338 |
| Metformin Hcl Generic | 56 | 166 | 21 | $646 |
Brand drugs: 1,855 claims; generic drugs: 1,514 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Smita N Kargutkar $1,716 ($1,716 in general payments such as food, travel and fees) from 23 companies. The largest payer was Xeris Pharmaceuticals, Inc. with $768.
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 6 | $768 |
| Corcept Therapeutics CORT | 11 | $172 |
| Amgen Inc. AMGN | 5 | $78.31 |
| Abbvie Inc. ABBV | 4 | $65.22 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $56.28 |
| Insulet Corporation PODD | 2 | $47.02 |
| IBSA Pharma Inc. | 3 | $46.8 |
| Lilly USA, LLC LLY | 3 | $46.15 |
| OPKO Pharmaceuticals, LLC | 1 | $44.4 |
| Recordati_rare_diseases_inc. | 2 | $34.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.